Infliximab for the treatment of rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn 2010, Issue 7, 2002, Pages

  Blumenauer, Barbara BTB ^a   Judd, Maria ^b   Wells, George A ^c   Burls, Amanda ^d   Cranney, Ann ^e   Hochberg, Marc C ^f   Tugwell, Peter ^e   Lopez Olivo, Maria Angeles ^g  

^a Utilisation de la Recherche ^*  (Canada)

^b Utilisation de la Recherche   (Canada)

^c UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; HUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS;

EID: 0042632287     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003785     Document Type: Review

References (21)

1. Lipsky PE, Van Der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. The New England Journal of Medicine 2000;343:1594-1602.
2. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrextae in rheumatoid arthritis. Arthritis and Rheumatism 1998;41(9):1552-1563.
3. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-1939.
4. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. British Journal of Rheumatology 1997;36:643-650.
5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibody to tumour necrosis factor alpha. Arthritis and Rheumatism 1993;36(12):1681-1690.
6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-1127.
7. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, MacFarlane JD, Bijl H, Woody JN. Randomized double-blind comparision of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
8. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor- alpha (cA2). British Journal of Rheumatology 1997;36:589-593.
9. Kalden-Nemeth D, Grebmeiser J, Antoni C, Manger B, Wolf F, Kalden JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF alpha monoclonal antibody therapy. Rheumatology International 1997;16:249-255.
10. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumour necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. Journal of Rheumatology 2000;27:841-850.
11. Oshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H, Shimizu M, Suemura M, McCloskey R, Kishimoto T. Long-term floow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha therapy. journal of Clinical Immunology 1999;19:305-313.
12. Perkins DJ, St Clair EW, Misukonis MA, Weinberg JB. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumour necrosis factor alpha monoclonal antibody (cA2). Arthritis and Rheumatism 1998;41(12):2205-2210.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-24.
14. Boers M, Tugwell P, Felson DT. World health organization and international league of associations for rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;21:86-9.
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1993;36:729-40.
16. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith D, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism 1995;38:727-35.
17. Jadad A, Moore A, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
18. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345(15):1098-1104.
19. OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. J Rheumatol 1993;20:526-91.
20. Pincus T, Stein CM. ACR20: clinical or statistical significance?. Arthritis Rheum 1999;42(8):1572-6.
21. [Remicade Product Label]. 2001.